Replimune Group, Inc. (REPL): who owns it and who trades it
As of Nov 16, 2026, REPL insiders reported 19 open-market sales worth $2.5M and no purchases in the last 12 months, with 11% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sushil Patel (CEO), with $811K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Replimune Group
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns REPL
198 funds and institutions reported REPL shares worth $1.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 13.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 11.05M | 13.16% | $122M | No change |
| BlackRock, Inc. | 8.96M | 10.67% | $99.2M | +44% |
| Rtw Investments, LP | 7.41M | 8.83% | $82M | +1% |
| Ridgeback Capital Investments L.P. | 7.31M | 8.71% | $80.9M | – |
| Goldman Sachs Group Inc | 4.54M | 5.41% | $50.3M | +99% |
| State Street Corp | 4.44M | 5.29% | $49.2M | +17% |
| Montanova Capital, LLC | 4.39M | 5.23% | $48.6M | +4% |
| Boxer Capital Management, LLC | 3.98M | 4.74% | $44.1M | +239% |
| Vanguard Capital Management LLC | 2.90M | 3.45% | $32.1M | +5% |
| Fcpm III Services B.v. | 2.81M | 3.35% | $31.1M | No change |
| AQR Capital Management LLC | 2.57M | 3.06% | $28.4M | +904% |
| Logos Global Management LP | 2.50M | 2.98% | $27.7M | – |
| Jane Street Group, LLC | 2.32M | 2.77% | $25.7M | +442% |
| Erste Asset Management GmbH | 2.12M | 2.53% | $23.7M | No change |
| Geode Capital Management, LLC | 2.04M | 2.42% | $22.5M | +13% |
| D. E. Shaw & Co., Inc. | 1.79M | 2.13% | $19.8M | -23% |
| T. Rowe Price Associates | 1.62M | 1.93% | $17.9M | -80% |
| Opaleye Management Inc. | 1.38M | 1.65% | $15.3M | – |
| Toronto Dominion Bank | 1.27M | 1.52% | $14.1M | -20% |
| UBS Group AG | 1.13M | 1.34% | $12.5M | +94% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, REPL insiders reported $0 of open-market purchases and $2.5M of sales. 11% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Joseph P Slattery | Director | Sale | 5,200 | $21.80 | $113K | Form 4 |
| Nov 2, 2026 | Kapil Dhingra | Director | Sale | 21,500 | $19.00 | $408K | Form 4 |
| Aug 17, 2026 | Emily Luisa Hill | CFO | Sale | 9,256 | $14.28 | $132K | Form 4 |
| Aug 10, 2026 | Sushil Patel | CEO | Sale | 39,341 | $12.97 | $510K | Form 4 |
| Aug 10, 2026 | Emily Luisa Hill | CFO | Sale | 11,448 | $12.97 | $148K | Form 4 |
| Aug 10, 2026 | Konstantinos Xynos | Chief Medical Officer | Sale | 11,447 | $12.97 | $148K | Form 4 |
| Aug 10, 2026 | Andrew Schwendenman | Chief Accounting Officer | Sale | 7,632 | $12.97 | $99K | Form 4 |
| Jun 1, 2026 | Christopher Sarchi | Chief Commercial Officer | Sale plan | 12,000 | $9.24 | $111K | Form 4 |
| May 18, 2026 | Konstantinos Xynos | Chief Medical Officer | Sale | 14,023 | $5.08 | $71.2K | Form 4 |
| May 18, 2026 | Andrew Schwendenman | Chief Accounting Officer | Sale | 7,894 | $5.08 | $40.1K | Form 4 |
| May 18, 2026 | Christopher Sarchi | Chief Commercial Officer | Sale | 8,626 | $5.08 | $43.8K | Form 4 |
| May 18, 2026 | Philip Astley-Sparke | Director | Sale | 17,657 | $5.08 | $89.7K | Form 4 |
| May 18, 2026 | Sushil Patel | CEO | Sale | 37,324 | $5.08 | $190K | Form 4 |
| May 18, 2026 | Emily Luisa Hill | CFO | Sale | 7,812 | $5.08 | $39.7K | Form 4 |
| Apr 2, 2026 | Christopher Sarchi | Chief Commercial Officer | Sale plan | 6,500 | $8.01 | $52.1K | Form 4 |
| Dec 9, 2025 | Kapil Dhingra | Director | Sale | 3,169 | $10.40 | $33K | Form 4 |
| Dec 2, 2025 | Sushil Patel | CEO | Sale plan | 10,000 | $11.13 | $111K | Form 4 |
| Nov 17, 2025 | Christopher Sarchi | Chief Commercial Officer | Sale | 5,208 | $9.10 | $47.4K | Form 4 |
| Nov 17, 2025 | Konstantinos Xynos | Chief Medical Officer | Sale | 7,248 | $9.10 | $66K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sushil Patel | Chief Executive Officer, Director | – | $811K | Aug 10, 2026 |
| Kapil Dhingra | Director | – | $441K | Nov 2, 2026 |
| Emily Luisa Hill | Chief Financial Officer | – | $320K | Aug 17, 2026 |
| Konstantinos Xynos | Chief Medical Officer | – | $286K | Aug 10, 2026 |
| Christopher Sarchi | Chief Commercial Officer | – | $254K | Jun 1, 2026 |
| Andrew Schwendenman | Chief Accounting Officer | – | $139K | Aug 10, 2026 |
| Joseph P Slattery | Director | – | $113K | Nov 9, 2026 |
| Philip Astley-Sparke | Director | – | $89.7K | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
REPL short interest
Very high short interest. 26.0% of REPL shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 4%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 24.61M REPL shares were sold short, 26.0% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.96M shares, buying them all back would take about 8.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 24.61M | 25.96% | +6% | 2.96M | 8.3 |
| Oct 15, 2026 | 23.17M | 27.60% | +0% | 1.82M | 12.7 |
| Sep 30, 2026 | 23.13M | 27.55% | +2% | 2.14M | 10.8 |
| Sep 15, 2026 | 22.75M | 27.11% | -3% | 2.04M | 11.1 |
| Aug 31, 2026 | 23.52M | 28.02% | -5% | 2.65M | 8.9 |
| Aug 14, 2026 | 24.87M | 29.62% | -10% | 6.28M | 4.0 |
| Jul 31, 2026 | 27.54M | 32.81% | +16% | 8.45M | 3.3 |
| Jul 15, 2026 | 23.65M | 28.18% | -0% | 2.50M | 9.4 |
| Jun 30, 2026 | 23.67M | 28.19% | +3% | 3.72M | 6.4 |
| Jun 15, 2026 | 22.89M | 27.72% | -12% | 4.73M | 4.8 |
| May 29, 2026 | 25.95M | 31.43% | +10% | 8.83M | 2.9 |
| May 15, 2026 | 23.66M | 28.65% | +12% | 8.36M | 2.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Replimune Group company events
Replimune Group filed 14 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 28, 2026.
- Oct 28, 2026ResultsReleased financial results. Filing
- Sep 16, 2026VoteReported shareholder vote results. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 11, 2026AnnouncementAmended an earlier report. The Company entered into an underwriting agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (each, an “Underwriter” and, collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of 9,701,490 shares of the Company’s common stock… Filing
- Aug 10, 2026AnnouncementReplimune Group, Inc. entered into an underwriting agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (each, an “Underwriter” and, collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of 9,701,490 shares of the Company’s… Filing
- Aug 7, 2026AnnouncementReplimune Group, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted accelerated approval for TUDRIQEV TM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced… Filing
- Jul 31, 2026AnnouncementReplimune Group, Inc. issued a press release announcing that the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee met to discuss the Company’s Biologics License Application resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for… Filing
- Jul 30, 2026AnnouncementShared information with investors. Filing
- Jun 29, 2026ResultsReleased financial results. Filing
- Jun 26, 2026AnnouncementShared information with investors. Filing
- May 29, 2026AnnouncementShared information with investors. Filing
- Apr 13, 2026AnnouncementThe Company received a second Complete Response Letter from the FDA regarding the Company’s BLA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. Filing
- Feb 3, 2026AgreementReplimune Group, Inc. and certain subsidiaries of the Company entered into a Third Amendment to Loan and Security Agreement with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent, and certain other financial institutions that from time to time may become parties… Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Replimune Group financials
Famous investors that hold REPL
3 of the 50 well-known investors we track reported holding REPL in their latest 13F filing. The largest position is Ken Griffin's, worth $16.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.27M | $16.8M | 0.0% | +62% |
| Israel Englander · Millennium Management | Q3 2026 | 522,183 | $6.9M | 0.0% | -36% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 206,800 | $2.7M | 0.0% | +420% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named REPL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 9.0% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 9.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G/A | 3.3% |
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G/A | 3.3% |
Questions about Replimune Group, Inc. (REPL) stock
Who owns the most REPL stock?
The largest reported owner of Replimune Group, Inc. (REPL) is Baker Bros. Advisors LP, with 13.2% of the company. In total, 198 funds and institutions reported holding REPL at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are REPL insiders buying or selling?
In the last 12 months, REPL insiders reported no open-market purchases and 19 sales worth $2.5M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in REPL?
As of Oct 30, 2026, 24.61M REPL shares were sold short, 26.0% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.96M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.
Which famous investors hold REPL?
3 of the 50 well-known investors we track reported REPL in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $16.8M. See all holders.
Executive pay
Replimune Group's chief executive was paid a total of $5.8M for the year ended Mar 31, 2026, up 58% from $3.7M the year before. In the last 12 months, Replimune Group's executives and directors bought no stock on the open market and sold $2.5M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.